Published in Br Med J on January 09, 1971
Serological response to filamentous hemagglutinin and lymphocytosis-promoting toxin of Bordetella pertussis. Infect Immun (1983) 1.77
Experimental pertussis infection in the marmoset: type specificity of active immunity. J Hyg (Lond) (1974) 1.31
Pertussis antibodies in the sera of children exposed to Bordetella pertussis by vaccination or infection. J Hyg (Lond) (1973) 1.16
Respiratory and humoral immune response to aerosol and intramuscular pertussis vaccine. J Hyg (Lond) (1975) 1.08
Efficacy of whooping-cough vaccines. Br Med J (1973) 0.82
Rapid diagnosis of whooping cough using monoclonal antibody. J Clin Pathol (1988) 0.75
Editorial: Vaccination against whooping cough. Br Med J (1974) 0.75
Technical problems in the laboratory diagnosis and prevention of whooping-cough. Lab Pract (1970) 3.05
Potency tests for pertussis vaccines: doubtful value of intracerebral challenge test in mice. J Pathol Bacteriol (1966) 2.73
Serotyping of Campylobacter jejuni/coli. J Clin Pathol (1980) 4.22
Technical problems in the laboratory diagnosis and prevention of whooping-cough. Lab Pract (1970) 3.05
Meningococcal infections in Bolton, 1971-74. Lancet (1975) 2.98
Potency tests for pertussis vaccines: doubtful value of intracerebral challenge test in mice. J Pathol Bacteriol (1966) 2.73
Diphtheria in the Manchester area 1967-1971. Lancet (1974) 2.70
Selective medium for the isolation of bordetella pertussis and parapertussis. J Clin Pathol (1972) 2.47
Toxoid vaccine for pertussis. Lancet (1997) 2.43
The epidemiology of meningococcal infections in England and Wales, 1912-1983. J Infect (1985) 2.22
A comparison of biotypes and serotypes of Campylobacter sp. isolated from patients with enteritis and from animal and environmental sources. J Infect (1984) 2.07
Efficacy of pertussis vaccines: a brighter horizon. Br Med J (1972) 2.04
The meningococcal carrier-rate. Lancet (1973) 1.89
Sensitivity of meningococci to sodium sulphadiazine and six antibiotics. J Med Microbiol (1970) 1.83
Salmonella infections in hospital. A report from the Public Health Laboratory Service Salmonella Subcommittee. J Hosp Infect (1980) 1.81
Serotype and sulphonamide sensitivity of meningococci isolated from 1966 to 1971. J Clin Pathol (1972) 1.80
Immunisation of adults against diphtheria. Br Med J (1978) 1.72
Protection by pertussis vaccine. Little cause for concern. Lancet (1976) 1.63
Change in serotype of pertussis infection in Britain. Lancet (1985) 1.60
Prevalent serotypes of Bordetella pertussis in non-vaccinated communities. J Hyg (Lond) (1976) 1.57
Variation of serotype in strains of Bordetella pertussis. J Hyg (Lond) (1974) 1.50
Measles control in young infants. Lancet (1993) 1.45
Polio eradication. Lancet (1994) 1.40
Serotyping of Campylobacter species by combined use of two methods. Eur J Clin Microbiol (1985) 1.38
Fatal case of Pasteurella pseudotuberculosis infection associated with hepatic cirrhosis. Br Med J (1967) 1.33
Experimental pertussis infection in the marmoset: type specificity of active immunity. J Hyg (Lond) (1974) 1.31
Identification of Vibrio cholerae by pyrolysis gas-liquid chromatography. Appl Microbiol (1973) 1.30
Diphtheria carriers in Manchester: simultaneous infection with toxigenic and non-toxigenic mitis strains. Lancet (1980) 1.29
Mouse or man? Which are pertussis vaccines to protect? J Hyg (Lond) (1976) 1.28
Whooping-cough in Hertfordshire. Lancet (1979) 1.27
Serological grouping of meningococci and detection of antigen in cerebrospinal fluid by coagglutination. Med Lab Sci (1978) 1.24
Application of three typing schemes (Penner, Lior, Preston) to strains of Campylobacter spp. isolated from three outbreaks. Epidemiol Infect (1987) 1.21
Letter: Whooping-cough vaccination. Lancet (1974) 1.19
Some unsolved problems with vaccines. Prog Drug Res (1979) 1.12
Down's syndrome with a familial D/D reciprocal translocation and a G/G chromosome. J Med Genet (1966) 1.12
The causes of severe mental handicap. Dev Med Child Neurol (1982) 1.12
A reappraisal of serotype factors 4, 5 and 6 of Bordetella pertussis. J Hyg (Lond) (1982) 1.11
Cholera vaccines: lessons from Rwanda and elsewhere. Lancet (1997) 1.10
Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers. Br J Cancer (2011) 1.08
Whooping cough in northern Israel. Isr J Med Sci (1972) 1.08
Antibiotic-sensitivity tests. Br Med J (1973) 1.05
Essential immunogens in human pertussis: the role of fimbriae. Dev Biol Stand (1985) 1.02
Experimental pertussis infection in the rabbit: similarities with infection in primates. J Infect (1980) 1.01
Meningococcal meningitis in Royal Air Force recruits. Public Health (1977) 1.00
Some factors affecting the haemolytic activity of Vibrio cholerae. J Med Microbiol (1974) 0.99
Pertussis agglutinins in vaccinated children: better response with adjuvant. J Hyg (Lond) (1974) 0.98
Recognising whooping cough. Br Med J (Clin Res Ed) (1986) 0.98
Accelerated immunisation with diphtheria-tetanus-pertussis vaccine. BMJ (1991) 0.98
An epidemic of meningococcal infection at Zaria, Northern Nigeria. 3. Meningococcal carriage. Trans R Soc Trop Med Hyg (1979) 0.96
Machakos project studies. Agents affecting health of mother and child in a rural area of Kenya. V. Pertussis sentypes in Kenyan children 1974--1975. Trop Geogr Med (1978) 0.95
Application of pulsed field gel electrophoresis to the 1993 epidemic of whooping cough in the UK. Epidemiol Infect (1995) 0.94
Lead absorption in children. Br Med J (1967) 0.92
The required number of treatment imaging days for an effective off-line correction of systematic errors in conformal radiotherapy of prostate cancer--a radiobiological analysis. Radiother Oncol (2001) 0.91
Pertussis agglutinins in vaccinated mice : difficulty in estimating the type-specific response. Indian J Med Res (1976) 0.91
Down syndrome: prevalence at birth, mortality and survival. A 17-year study. Early Hum Dev (1979) 0.90
Histamine-sensitising factor of Bordetella pertussis differentiated from immunogens by neutralisation and passive protection tests. J Pathol Bacteriol (1967) 0.90
Whooping cough in West Germany. Lancet (1985) 0.88
Daily monitoring of linear accelerator beam parameters using an amorphous silicon EPID. Phys Med Biol (2007) 0.85
Toxicity of pertussis vaccine. Br Med J (Clin Res Ed) (1982) 0.83
What makes a good pertussis vaccine? Prog Drug Res (1975) 0.82
Efficacy of whooping-cough vaccines. Br Med J (1973) 0.82
Quantitative analysis of patient-specific dosimetric IMRT verification. Phys Med Biol (2005) 0.81
Improving IMRT quality control efficiency using an amorphous silicon electronic portal imager. Med Phys (2005) 0.81
Vaccine composition in relation to antigenic variation of the microbe: is pertussis unique? Prog Drug Res (1975) 0.80
Characterization of outbreak and vaccine strains of Bordetella pertussis--Quebec. Can Commun Dis Rep (1993) 0.80
Current pharmacotherapy of pertussis. Expert Opin Pharmacother (2001) 0.79
A novel imaging technique for fusion of high-quality immobilised MR images of the head and neck with CT scans for radiotherapy target delineation. Br J Radiol (2009) 0.79
Type-specific action of vibriocidal antibody on Vibrio cholerae. J Hyg (Lond) (1975) 0.78
Modelling the throughput capacity of a single-accelerator multitreatment room proton therapy centre. Br J Radiol (2012) 0.78
Pertussis component vaccine in Japan. Lancet (1984) 0.78
Radiotherapy research priorities for the UK. Clin Oncol (R Coll Radiol) (2010) 0.78
Association between Bordetella pertussis agglutinogen 2 and fimbriae. J Med Microbiol (1984) 0.77
The use of a realistic VMAT delivery emulator to optimize dynamic machine parameters for improved treatment efficiency. Phys Med Biol (2011) 0.77
Pulmonary pertussis infection in the mouse: no solution to an old problem. J Infect (1981) 0.76
Transmission of pertussis: do adults have an important role? Lancet (1996) 0.76
Assessing the response to pertussis vaccine. BMJ (1991) 0.75
Methodological considerations in the evaluation of radiotherapy technologies. Clin Oncol (R Coll Radiol) (2012) 0.75
Components of acellular pertussis vaccines. Lancet (1996) 0.75
Diphtheria, pertussis, and tetanus vaccination. Lancet (1992) 0.75
Cholera treatment. Lancet (1994) 0.75
Meningococcal infection: serotypes and suplhonamide sensitivity. J Clin Pathol (1972) 0.75
Immunological and bacteriological distinction between parapertussis and pertussis. Lancet (1995) 0.75
Cholera isolates in relation to the "eighth pandemic". Lancet (1993) 0.75
Changing advice on vaccination. Br Med J (1979) 0.75
Measles and pertussis: the timing of vaccination. Lancet (1995) 0.75
Letter: Immunisation against whooping cough. Br Med J (1976) 0.75
Publication bias via suppressed expert conflict. Lancet (1993) 0.75
Immunisation of the preterm baby. J Infect (1994) 0.75
Acellular pertussis vaccines: progress but déjà vu. Lancet (1998) 0.75
Influence of challenge strain on potency of pertussis vaccines in mice. Nature (1967) 0.75
Antigens that modern vaccines must contain. Lancet (1990) 0.75
Viruses and whooping-cough. Lancet (1972) 0.75
Pertussis vaccine efficacy in Birmingham. Commun Dis Public Health (2000) 0.75
The motility of some clostridium species. J Gen Microbiol (1969) 0.75
Fate of the severly subnormal. Dev Med Child Neurol (1966) 0.75
Whooping cough vaccine efficacy. Lancet (1982) 0.75
Whooping-cough immunization: fact and fiction. Public Health (1980) 0.75
Pertussis antibodies in vaccinated children. Lancet (1983) 0.75
Marvin: an anatomical phantom for dosimetric evaluation of complex radiotherapy of the head and neck. Phys Med Biol (2013) 0.75
Campylobacter serotypes and epidemiology. Lancet (1981) 0.75
Whooping-cough vaccination. Br Med J (1979) 0.75